Sector: Health Technology
Industry: Biotechnology
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
Market Capitalization
115.522M
Total Shares Outstanding (MRQ)
54.236M
Net Debt (MRQ)
-56.821M
Total Assets (MRQ)
97.745M
Revenue per Employee (TTM)
9518.5185
Free Cash Flow (TTM)
-39.883M :(, but it's BIO and other indicators look good.
Phase 2-3 trials, FDA looking at turning decision from June that scared off investors.
Analyst upgrade to 7
Industry: Biotechnology
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
Market Capitalization
115.522M
Total Shares Outstanding (MRQ)
54.236M
Net Debt (MRQ)
-56.821M
Total Assets (MRQ)
97.745M
Revenue per Employee (TTM)
9518.5185
Free Cash Flow (TTM)
-39.883M :(, but it's BIO and other indicators look good.
Phase 2-3 trials, FDA looking at turning decision from June that scared off investors.
Analyst upgrade to 7